Neurology News

The U.S. Senate recently passed legislation that would make daylight saving time permanent starting in 2023.

An increased risk for cognitive decline was associated with adults aged 60 years and older, following severe cases of COVID-19, in Wuhan, China, experts reported in JAMA Neurology.

Biopharmaceutical company Corium announced that the FDA has approved Adlarity to treat patients with mild, moderate or severe dementia associated with Alzheimer’s disease, according to a press release.

Pharmaceutical company Lupin announced that the FDA has approved its abbreviated new drug application for anti-epileptic vigabatrin for oral solution, according to a press release.

Neurotechnology company Cognito Therapeutics announced a partnership with Aetion to develop a validated predictive model that will help identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.

The passage of the Build Back Better Act by the Senate has been put on the back burner. But it makes sense for high-income earners and those with large retirement account balances to understand the provisions in the version of the bill passed by the U.S. House of Representatives in November 2021.

After a long winter, the switch to daylight saving time on March 13 may seem like a welcome sign of spring.

Concussion was linked to increased risk for mental health issues, psychiatric hospitalization and self-harm among youths aged 5 to 18 years, according to results of a population-based retrospective cohort study.

High alcohol use was associated with more severe neurodegeneration and smoking was linked with greater probability of MS diagnosis, according to a U.K. study published in JAMA Network Open.

The American Academy of Neurology noted palliative care can benefit individuals with neurologic diseases and may lead to longer survival when provided early in the disease process.